RFM
IBB icon

Royal Fund Management’s iShares Biotechnology ETF IBB Stock Holding History

Royal Fund Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,955
Closed -$1.3M – 316
2024
Q3 		$1.3M Buy
+8,955
New +$1.3M 0.08% 193
2018
Q3 		– Sell
-7
Closed – – 576
2018
Q2 		$0 Sell
7
-11
-61% -$1.18K ﹤0.01% 589
2018
Q1 		$1K Buy
+18
New +$2K ﹤0.01% 491

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Fund Management's IBB Position: Q4 2024 in Review

Royal Fund Management sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 8,955 shares — an estimated $1.3M sold.

Royal Fund Management first reported a position in IBB in Q1 2018 and held it in 3 quarters. The position peaked at $1.3M in Q3 2024. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2024.

  • Royal Fund Management reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
  • Royal Fund Management sold 8,955 iShares Biotechnology ETF shares in Q4 2024, an estimated $1.3M.
  • Royal Fund Management first reported a position in iShares Biotechnology ETF in Q1 2018 and held it in 3 quarters.
  • Royal Fund Management's iShares Biotechnology ETF position peaked at $1.3M in Q3 2024.
  • 874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.

Based on Royal Fund Management's 13F filing for Q4 2024, filed 16 Jan 2025.